Pacritinib (SB1518), a JAK2/FLT3 inhibitor for the treatment of acute myeloid leukemia

FMS-like tyrosine kinase 3 (FLT3) is the most commonly mutated gene found in acute myeloid leukemia (AML) patients and its activating mutations have been proven to be a negative prognostic marker for clinical outcome. Pacritinib (SB1518) is a tyrosine kinase inhibitor (TKI) with equipotent activity...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Main Authors: Hart, S, Goh, K C, Novotny-Diermayr, V, Tan, Y C, Madan, B, Amalini, C, Ong, L C, Kheng, B, Cheong, A, Zhou, J, Chng, W J, Wood, J M
Formato: Artigo
Idioma:Inglês
Publicado em: Nature Publishing Group 2011
Assuntos:
Original Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC3256753/
https://ncbi.nlm.nih.gov/pubmed/22829080
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/bcj.2011.43
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados